Register
Get access to our best features
Subscribe

Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

Summary by Ground News
Six additional weeks of rivaroxaban reduces risk for recurrent venous thromboembolism. In 40 and 43 percent of patients, isolated distal DVT was unprovoked. Proximal DVT or pulmonary embolism occurred in 3 and 4% of patients.
Published 2 months ago · Boone, United States

News Articles

More Filters
All
Left
Center
Right
HealthDayHealthDay

Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE

WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, according to a study published…

2 months ago
Read Full Article

Similar News Topics

Boone, North CarolinaBoone, North Carolina
Show All
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

No sources with tracked biases.
See less detail
Trending Topics
Ground News logo
US
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogSubscribeGiftCareersFor Educators/Libraries
HelpHelp CenterFAQMedia Bias RatingsOwnership and Factuality RatingsInterestsContact UsReferral Code
ToolsBrowser ExtensionRehashMediaopolyTwitter BlindspotterDaily NewsletterBlindspot Report NewsletterBurst Your Bubble Newsletter
DonatePrivacy PolicyTerms and Conditions
© 2022 Snapwise Inc.
News
Feed
SearchBlindspotLocal